Where Batch Record Review Burns Time and Money
The review cycle for a single biologic batch can involve hundreds of data entry fields, multiple exception logs, and a chain of OOS investigation phases — each requiring a formatted narrative tied to specific regulatory citations. Pulling that work through MasterControl and EBR system logs manually, then reconciling executed records against master batch records, is a task that qualified QA staff spend weeks on per batch. The per-batch contractor cost compounds across a high-volume CMO calendar.
An AI Agent Wired Into MasterControl and EBR Workflows
An AI Labor Company agent mines exception and OOS investigation workflows directly from QA team MasterControl and EBR system logs. It auto-compares each executed batch record field against the master batch record, surfaces discrepancies, flags incomplete data entries, and drafts Phase-I OOS investigation narratives formatted to FDA 2006 OOS guidance. The QP or QA Release Manager reviews each deviation and approves disposition — the agent eliminates the assembly work, not the professional judgment.
The Business Case: Contractor Spend and Release Cycle Time
Batch record review is a direct cost line that scales with volume. An agent that handles the comparison and drafting work can reduce QA contractor hours by roughly 40% per batch — and across a CMO calendar with dozens of batches per quarter, that compounds quickly. Beyond the cost reduction, faster first-pass reviews mean shorter release cycles, which lets the CMO turn capacity faster and take on more client programs without proportionally expanding the QA team. The agent is typically live in about ten weeks.
Can the agent handle both electronic batch records and paper-based records that have been scanned?
The agent works natively with EBR system logs and MasterControl workflows. Scanned paper records can be ingested via OCR preprocessing, though accuracy on handwritten fields may require a human verification step.
How does the agent stay current with FDA OOS guidance updates?
The agent's OOS narrative templates are maintained against the current FDA 2006 OOS guidance and can be updated by the QA team when guidance changes. Updates to templates do not require a system revalidation — they are managed as controlled documents.